Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Charlotte M. Huijts"'
Autor:
Saraswati Sukumar, Zaver M. Bhujwalla, Vered Stearns, Chi V. Dang, Hualing Tsai, Cesar A. Santa-Maria, Zhe Zhang, Santosh Bharti, Flonne Wildes, Charlotte M. Huijts, Noriko Mori, Liangfeng Han, Helen Sadik, Wei Wen Teo, Preethi Korangath
Supplementary methods and figures S1-S8. (S1): Glutamine dependency and induction of apoptosis on glutamine withdrawal in breast cancer cells. (S2): Cytotoxicity of AOA in breast cancer cells. (S3): Myc regulation of transaminases and glutamine depen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73b9ea4ba7125e20b924844c447f066f
https://doi.org/10.1158/1078-0432.22458965.v1
https://doi.org/10.1158/1078-0432.22458965.v1
Autor:
Saraswati Sukumar, Zaver M. Bhujwalla, Vered Stearns, Chi V. Dang, Hualing Tsai, Cesar A. Santa-Maria, Zhe Zhang, Santosh Bharti, Flonne Wildes, Charlotte M. Huijts, Noriko Mori, Liangfeng Han, Helen Sadik, Wei Wen Teo, Preethi Korangath
Purpose: Glutamine addiction in c-MYC–overexpressing breast cancer is targeted by the aminotransferase inhibitor, aminooxyacetate (AOA). However, the mechanism of ensuing cell death remains unresolved.Experimental Design: A correlation between glut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12cfd2519b3b1b77451b24548a02d448
https://doi.org/10.1158/1078-0432.c.6524099
https://doi.org/10.1158/1078-0432.c.6524099
Autor:
Paul Hamberg, John B. A. G. Haanen, Hans van Vliet, Metin Tascilar, Zuhir Bodalal, Tanja D. de Gruijl, Carla M.L. van Herpen, Henk M.W. Verheul, Sinéad M. Lougheed, Charlotte M. Huijts
Publikováno v:
Huijts, C M, Lougheed, S M, Bodalal, Z, van Herpen, C M, Hamberg, P, Tascilar, M, Haanen, J B, Verheul, H M, de Gruijl, T D, van der Vliet, H J & Dutch WIN-O Consortium 2019, ' The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial ', Cancer Immunology, Immunotherapy, vol. 68, no. 3, pp. 503-515 . https://doi.org/10.1007/s00262-018-2288-8
Cancer Immunology, Immunotherapy, 68(3), 503-515. Springer Science and Business Media Deutschland GmbH
Cancer Immunology, Immunotherapy
Cancer Immunology Immunotherapy, 68, 503-515
Cancer Immunology Immunotherapy, 68, 3, pp. 503-515
Cancer Immunology, Immunotherapy, 68(3), 503-515. Springer Science and Business Media Deutschland GmbH
Cancer Immunology, Immunotherapy
Cancer Immunology Immunotherapy, 68, 503-515
Cancer Immunology Immunotherapy, 68, 3, pp. 503-515
For the treatment of metastatic renal cell cancer several strategies are used among which the mTOR inhibitor everolimus. As mTOR plays an important role in the immune system, e.g., by controlling the expression of the transcription factor FoxP3 there
Autor:
Tanja D. de Gruijl, Hans J. van der Vliet, Charlotte M. Huijts, Saskia J. A. M. Santegoets, Tamarah D. de Jong, Henk M.W. Verheul
Publikováno v:
International Journal of Immunopathology and Pharmacology, 30(4), 341-352. SAGE Publications Inc.
International Journal of Immunopathology and Pharmacology
Huijts, C M, Santegoets, S J, de Jong, T D, Verheul, H M, de Gruijl, T D & van der Vliet, H J 2017, ' Immunological effects of everolimus in patients with metastatic renal cell cancer ', International Journal of Immunopathology and Pharmacology, vol. 30, no. 4, pp. 341-352 . https://doi.org/10.1177/0394632017734459
International Journal of Immunopathology and Pharmacology
Huijts, C M, Santegoets, S J, de Jong, T D, Verheul, H M, de Gruijl, T D & van der Vliet, H J 2017, ' Immunological effects of everolimus in patients with metastatic renal cell cancer ', International Journal of Immunopathology and Pharmacology, vol. 30, no. 4, pp. 341-352 . https://doi.org/10.1177/0394632017734459
The mammalian target of rapamycin (mTOR) is a crucial kinase present in all cells. Besides its role in the regulation of cell-growth, proliferation, angiogenesis, and survival of malignant tumors, mTOR additionally plays an important role in immune r
Autor:
Tanja D. de Gruijl, John B. A. G. Haanen, Ruben S.A. Goedegebuure, Metin Tascilar, Charlotte M. Huijts, Hans J. van der Vliet, Paul Hamberg, Carla M.L. van Herpen, Sinéad M. Lougheed, Henk M.W. Verheul, Inge M. Werter
Publikováno v:
Cancer Immunology Immunotherapy, 68, 319-329
Cancer Immunology, Immunotherapy
Cancer Immunology, Immunotherapy, 68(2), 319-329. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 2, pp. 319-329
Huijts, C M, Werter, I M, Lougheed, S M, Goedegebuure, R S, van Herpen, C M, Hamberg, P, Tascilar, M, Haanen, J B, Verheul, H M, de Gruijl, T D, van der Vliet, H J & Dutch WIN-O Consortium 2019, ' Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma ', Cancer Immunology, Immunotherapy, vol. 68, no. 2, pp. 319-329 . https://doi.org/10.1007/s00262-018-2248-3
Cancer Immunology, Immunotherapy
Cancer Immunology, Immunotherapy, 68(2), 319-329. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 2, pp. 319-329
Huijts, C M, Werter, I M, Lougheed, S M, Goedegebuure, R S, van Herpen, C M, Hamberg, P, Tascilar, M, Haanen, J B, Verheul, H M, de Gruijl, T D, van der Vliet, H J & Dutch WIN-O Consortium 2019, ' Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma ', Cancer Immunology, Immunotherapy, vol. 68, no. 2, pp. 319-329 . https://doi.org/10.1007/s00262-018-2248-3
Background: For patients with metastatic renal cell cancer (mRCC) who progressed on vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor therapy, the orally administered mammalian target of rapamycin (mTOR) inhibitor everolimu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae8fdb5bbd71bdebabc2536636937a5e
http://hdl.handle.net/2066/202111
http://hdl.handle.net/2066/202111
Autor:
Charlotte M. Huijts, Hans J. van der Vliet, Saskia J. A. M. Santegoets, Maria Quiles del Rey, Richard R. de Haas, Tanja D. de Gruijl, Henk M.W. Verheul
Publikováno v:
Clinical Immunology, 168, 47-54. Academic Press Inc.
Huijts, C M, Santegoets, S J, del Rey, M Q, de Haas, R R, Verheul, H M, de Gruijl, T D & van der Vliet, H J 2016, ' Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells ', Clinical Immunology, vol. 168, pp. 47-54 . https://doi.org/10.1016/j.clim.2016.05.005
Huijts, C M, Santegoets, S J, del Rey, M Q, de Haas, R R, Verheul, H M, de Gruijl, T D & van der Vliet, H J 2016, ' Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells ', Clinical Immunology, vol. 168, pp. 47-54 . https://doi.org/10.1016/j.clim.2016.05.005
The PI3K/mTOR pathway is commonly deregulated in cancer. mTOR inhibitors are registered for the treatment of several solid tumors and novel inhibitors are explored clinically. Notably, this pathway also plays an important role in immunoregulation. Wh
Autor:
Henk M.W. Verheul, Tanja D. de Gruijl, Marco B. Polee, Paul Hamberg, Charlotte M. Huijts, Maartje Los, Inge M. Werter, Sinéad. M. Lougheed, Hans van Vliet, John B. A. G. Haanen, Helgi H. Helgason, Metin Tascilar
Publikováno v:
Werter, I M, Huijts, C M, Lougheed, S M, Hamberg, P, Polee, M B, Tascilar, M, Los, M, Haanen, J B A G, Helgason, H H, Verheul, H M, de Gruijl, T D, van der Vliet, H J & Dutch WIN-O Consortium 2019, ' Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus ', Cancer Immunology, Immunotherapy, vol. 68, no. 5, pp. 787-798 . https://doi.org/10.1007/s00262-019-02313-z
Cancer Immunology, Immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 5, pp. 787-798
Cancer immunology, immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 787-798
Cancer Immunology, Immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 5, pp. 787-798
Cancer immunology, immunotherapy, 68(5), 787-798. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 787-798
Contains fulltext : 207393.pdf (Publisher’s version ) (Open Access) INTRODUCTION: Metastatic renal cell cancer (mRCC) patients have a median overall survival (mOS) of approximately 28 months. Until recently, mammalian target of rapamycin (mTOR) inh
Autor:
Tanja D. de Gruijl, Henk M.W. Verheul, Martine Reijm, Hetty J. Bontkes, Famke L. Schneiders, Hans J. van der Vliet, Charlotte M. Huijts
Publikováno v:
Immunobiology, 223(2), 171-177. Urban und Fischer Verlag GmbH und Co. KG
Schneiders, FL, Huijts, CM, Reijm, M, Bontkes, HJ, Verheul, HMW, de Gruijl, TD & van der Vliet, JJ 2018, ' The effects of systemic treatment with aminobisphosphonates and statins on circulating Vγ9Vδ2-T cells in patients with advanced cancer ', Immunobiology, vol. 223, no. 2, pp. 171-177 . https://doi.org/10.1016/j.imbio.2017.10.029
Schneiders, FL, Huijts, CM, Reijm, M, Bontkes, HJ, Verheul, HMW, de Gruijl, TD & van der Vliet, JJ 2018, ' The effects of systemic treatment with aminobisphosphonates and statins on circulating Vγ9Vδ2-T cells in patients with advanced cancer ', Immunobiology, vol. 223, no. 2, pp. 171-177 . https://doi.org/10.1016/j.imbio.2017.10.029
Aminobisphosphonates (NBP) are used for treatment of metastatic bone disease. Frequently, patients undergoing NBP-treatment experience side-effects, known as acute phase response (APR), resulting from cytokine production by Vγ9Vδ2-T cells. As oppos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f221cecdcdc376dfd88bdceca90131b1
https://research.vumc.nl/en/publications/5e16d094-d101-4582-b559-0cd4feb79652
https://research.vumc.nl/en/publications/5e16d094-d101-4582-b559-0cd4feb79652
Autor:
Zaver M. Bhujwalla, Chi V. Dang, Zhe Zhang, Hua-Ling Tsai, Charlotte M. Huijts, Flonne Wildes, Noriko Mori, Santosh Kumar Bharti, Liangfeng Han, Saraswati Sukumar, Wei Wen Teo, Cesar A. Santa-Maria, Helen Sadik, Preethi Korangath, Vered Stearns
Publikováno v:
Clinical Cancer Research. 21:3263-3273
Purpose: Glutamine addiction in c-MYC–overexpressing breast cancer is targeted by the aminotransferase inhibitor, aminooxyacetate (AOA). However, the mechanism of ensuing cell death remains unresolved. Experimental Design: A correlation between glu
Autor:
Hans J. van der Vliet, Aslihan Mantici, Henk M.W. Verheul, Emmanuel Scotet, Famke L. Schneiders, R. Veerhuis, Tanja D. de Gruijl, Charlotte M. Huijts, Mica A.C. Menks
Publikováno v:
Clinical Immunology
Clinical Immunology, 2015, 158 (92-99), ⟨10.1016/j.clim.2015.03.007⟩
Clinical Immunology, Elsevier, 2015, 158 (92-99), ⟨10.1016/j.clim.2015.03.007⟩
Schneiders, F L, Huijts, C M, Mantici, A, Menks, M A C, Scotet, E, Veerhuis, R, Verheul, H M W, de Gruijl, T D & van der Vliet, H J 2015, ' Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells ', Clinical Immunology, vol. 158, no. 1, pp. 92-99 . https://doi.org/10.1016/j.clim.2015.03.007
Clinical Immunology, 158(1), 92-99. Academic Press Inc.
Clinical Immunology, 2015, 158 (92-99), ⟨10.1016/j.clim.2015.03.007⟩
Clinical Immunology, Elsevier, 2015, 158 (92-99), ⟨10.1016/j.clim.2015.03.007⟩
Schneiders, F L, Huijts, C M, Mantici, A, Menks, M A C, Scotet, E, Veerhuis, R, Verheul, H M W, de Gruijl, T D & van der Vliet, H J 2015, ' Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells ', Clinical Immunology, vol. 158, no. 1, pp. 92-99 . https://doi.org/10.1016/j.clim.2015.03.007
Clinical Immunology, 158(1), 92-99. Academic Press Inc.
CD1d-restricted invariant natural killer T (iNKT) cells constitute an important immunoregulatory T cell subset that can be activated by the synthetic glycolipid α-galactosylceramide (α-GalCer) and initiate antitumor immune responses. As cancer pati